BioNTech (BNTX) Stock: Buy, Sell, or Hold?
BNTX - BioNTech SE American Depositary Share
$96.73
0.33 (0.34%)
â˛
5d:
-5.98%
30d:
+4.3%
90d:
+8.03%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Get Alerted When BNTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BNTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BNTX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BNTX is currently trading at $96.73, which is considered fair relative to its 30-day fair value range of $91.94 to $108.51.
Technical Outlook: Technically, BNTX is in a uptrend. The price is currently testing key support at $95.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BNTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $119.02 (+23.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BNTX is in a uptrend. The price is currently testing key support at $95.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BNTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $119.02 (+23.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$91.94 -
$108.51
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.0% below Wall St target ($119.02)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$91.94 -
$108.51
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$95.85
Resistance Level
$105.46
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.74
Wall Street Target
$119.02
(+23.0%)
Revenue Growth (YoY)
-59.5%
Earnings Growth (YoY)
-43.2%
Profit Margin
-63.6%
Share & Embed Analysis
Last updated: September 12, 2026 6:07 PM ET
Data refreshes hourly during market hours. Next update: 7:07 PM
Data refreshes hourly during market hours. Next update: 7:07 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Sierk Poetting
SELL
50000 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
